Le Lézard
Classified in: Health, Business
Subjects: JVN, MAT

Aurora Cannabis Accelerates European Expansion With Licensed Denmark Joint Venture


Planned 1,000,000 Square Foot High-Tech Facility Will Establish "Aurora Nordic Cannabis"
as Europe's Largest Cannabis Producer

TSX: ACB

EDMONTON, Jan. 4, 2018 /CNW/ - Aurora Cannabis Inc. ("Aurora") (TSX: ACB) (OTCQB: ACBFF) (Frankfurt: 21P; WKN: A1C4WM) today announced that the Company has signed a binding term sheet for the formation of a joint venture ("JV") with Alfred Pedersen & Søn ("APS"), pursuant to which Aurora will ultimately own a 51% interest in Aurora Nordic Cannabis A/S, the joint venture company, which is based in Odense, Denmark. Aurora and APS anticipate completing the final agreement shortly, governing the formation of the joint venture, subsequent to which Aurora Nordic will commence construction of an ALPS (Aurora Larssen Projects Ltd) designed, 1,000,000 square foot high-technology, fully automated cannabis production facility.

APS received its license to cultivate cannabis from Lægemiddelstyrelsen, Denmark's Medicines Agency, effective January 1, 2018. This gives Aurora Nordic a major advantage as one of few companies with a license to cultivate in Europe.

The new facility will be largely similar to Aurora`s flagship facility, Aurora Sky, with a projected production capacity in excess of 120,000 kg per annum. Construction will be phased, with cultivation commencing upon completion of the first 200,000 square feet, which is anticipated in the third quarter of calendar 2018. The new facility, upon completion, would establish Aurora Nordic as the continent`s largest producer of cannabis. Furthermore, through Aurora`s wholly owned subsidiary, Pedanios GmbH, Aurora Nordic will have access to Europe`s largest distributor of cannabis, providing direct access to a large and rapidly growing customer base.

Through APS, Aurora Nordic has access to existing greenhouse space it could utilize for cultivation as of the summer of 2018 if the company so chooses.

Under the terms of the agreement, and upon the achievement of certain milestones by the JV, the companies intend to fund construction of the Aurora Nordic facility through a combination of conventional, non-dilutive project finance, and direct investment by Aurora and APS on a pro-rata basis.

Aurora Nordic will focus on the cultivation and sales of cannabis in Denmark, Sweden, Norway, Finland and Iceland, through Aurora's wholly-owned subsidiary Pedanios GmbH. As capacity from the Aurora Nordic facility expands, excess capacity will be distributed to other EU countries with the support of Pedanios.

"This is a huge next step for Aurora, establishing us as the leading cannabis company in Europe, a market of well over 400 million people, dramatically accelerating our international expansion," said Terry Booth, CEO. "We are already the leading exporter to and distributor of medical cannabis in Germany, and now have the largest funded capacity footprint in the rapidly-growing European market, in which only a handful of licensed cannabis companies are currently able to operate."

Mr. Booth added, "The relationship between APS and Larssen, who identified this opportunity for us, goes back many years through the joint development of a number of large-scale projects. This provides Aurora Nordic with a major advantage in terms of time to market and overall execution. We will be able to utilize the operational capacity of one of the largest greenhouse vegetable growers in Europe (APS), in addition to Aurora's deep store of cannabis sector expertise, from growing to distribution. Furthermore, Mads Pedersen, APS's CEO, is a highly respected entrepreneur in the Nordic countries, and we will be able to leverage his strong industry and financial sector network to execute on Aurora Nordic's development and growth on favourable terms. We are very excited about this new venture, and look forward to be working closely with the APS team on establishing Aurora Nordic as the dominant cannabis company in the European market."

"We are delighted to partner with the world`s most dynamic cannabis company, with its exceptional execution track record," said Mads Pedersen, CEO of APS. "Aurora shares our high-technology, high-quality and ultra-low cost production philosophy. That, in addition to the clear strategic vision of Terry Booth, made Aurora our partner of choice to develop the full potential of our cannabis license and build Europe's leading cannabis company." 

Aurora's joint venture partner APS is one of Europe's largest greenhouse producers of tomatoes and other vegetables, and is known for achieving excellent yields per square foot. APS, which operates 3,000,000 square foot of greenhouse production space, currently ships up to 100,000 kg of greenhouse vegetable produce per day, requiring high levels of automation and a sophisticated logistical infrastructure. APS CEO Mads Pedersen was awarded, by PWC the accolade of "Business Owner of the Year" for 2017 in Denmark. Mr. Pedersen and his team will bring to Aurora Nordic important operational capacity, as well as a strong local network of suppliers, finance and logistics partners.

About Aurora

Aurora's wholly-owned subsidiary, Aurora Cannabis Enterprises Inc., is a licensed producer of medical cannabis pursuant to Health Canada's Access to Cannabis for Medical Purposes Regulations ("ACMPR"). The Company operates a 55,200 square foot, state-of-the-art production facility in Mountain View County, Alberta, known as "Aurora Mountain", a second 40,000 square foot high-technology production facility known as "Aurora Vie" in Pointe-Claire, Quebec on Montreal's West Island, and is currently constructing an 800,000 square foot production facility, known as "Aurora Sky", at the Edmonton International Airport, as well as is completing a fourth facility in Lachute, Quebec through its wholly owned subsidiary Aurora Larssen Projects Ltd.

In addition, the Company holds approximately 17.23% of the issued shares in leading extraction technology company Radient Technologies Inc., based in Edmonton, and is in the process of completing an investment in Edmonton-based Hempco Food and Fiber for an ownership stake of up to 50.1%. Furthermore, Aurora is the cornerstone investor with a 22.9% stake in Cann Group Limited, the first Australian company licensed to conduct research on and cultivate medical cannabis. Aurora also owns Pedanios, a leading wholesale importer, exporter, and distributor of medical cannabis in the European Union, based in Germany. The Company offers further differentiation through its acquisition of BC Northern Lights Ltd. and Urban Cultivator Inc., industry leaders, respectively, in the production and sale of proprietary systems for the safe, efficient and high-yield indoor cultivation of cannabis, and in state-of-the-art indoor gardening appliances for the cultivation of organic microgreens, vegetables and herbs in home and professional kitchens. Aurora's common shares trade on the TSX under the symbol "ACB".

About Alfred Pedersen & Søn

Alfred Pedersen & Søn is the largest tomato and sweet pepper grower in Scandinavia, with a total of 2.8 million square feet (26 hectares) cultivation space under glass. APS is the largest producer in Scandinavia of both conventional and organic tomatoes, and the leading grower of pepper and cucumber, all produced in state of art greenhouses. The company is widely-recognized for consistently being at the forefront of innovation.

On behalf of the Boards of Directors,                                    

AURORA CANNABIS INC.                                                  
Terry Booth                                                                            
CEO                                                                                                                                

This news release includes statements containing certain "forward-looking information" within the meaning of applicable securities law ("forward-looking statements"), including, but not limited to, statements with respect to the completion of Aurora Sky. Forward-looking statements are frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. These statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking statements throughout this news release. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.

Neither TSX nor its Regulation Services Provider (as that term is defined in the policies of Toronto Stock Exchange) accept responsibility for the adequacy or accuracy of this release.

SOURCE Aurora Cannabis Inc.


These press releases may also interest you

at 05:15
Every year in Quebec, more than 2,000 young people leave the care of the Director of Youth Protection (DYP) as they approach the age of majority. For youth under the care of the DYP, turning 18 means having to become independent quickly, with little...

at 03:00
ARTHEx Biotech S.L., a clinical-stage biotechnology company focused on developing innovative medicines through the modulation of microRNAs, today announced an oral presentation at the upcoming Oligonucleotide & Peptide Therapeutics (TIDES) Conference...

at 02:32
With every successive year, the lines between medical devices and consumer electronics become increasingly blurred ? medtech companies seek to expand their reach beyond patients, and consumer electronics companies have targeted medical applications...

18 avr 2024
The 31st Canadian Cancer Society (CCS) Daffodil Ball, which took place this evening at Windsor Station in Montreal, raised $1,474,785 to fund innovative research projects and essential support programs for people living with cancer. The largest...

18 avr 2024
The report titled "Clinical Trials Matching Software Market by Functionality (Analytics & Reporting, Compliance Tracking, Data Management), Deployment (Cloud & Web Based, On-Premise), End-Use - Global Forecast 2024-2030" is now available on...

18 avr 2024
South Korea's biotechnology company Hyundai Bioscience (CEO Oh Sang-gi, www.hyundaibioscience.com) announced on April 15 that it would carry out global clinical tests aimed at treating all serotypes of Dengue virus infection....



News published on and distributed by: